🔗 Visit the ClinicalTrials.gov page for NCT02748889
Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. | N Engl J Med | 2012 | 35.24 |
2 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. | N Engl J Med | 2015 | 11.98 |
3 | Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. | Cancer Immunol Immunother | 2004 | 2.42 |
4 | Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. | Cancer Immunol Immunother | 2006 | 2.20 |
5 | Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. | Ann Oncol | 2012 | 2.14 |
6 | Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. | J Clin Oncol | 2012 | 1.43 |